-
March 22, 2022
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference
-
January 5, 2022
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
-
January 4, 2022
Aileron Therapeutics to Present at Upcoming Investor Conferences
-
December 20, 2021
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs
-
November 12, 2021
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights
-
October 7, 2021
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity
-
September 30, 2021
Aileron Therapeutics Announces Presentation of New Preclinical Data at Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
-
September 16, 2021
Aileron Therapeutics Presents New Clinical Data at ESMO Virtual Congress 2021 Supporting ALRN-6924’s Best-in-Class Potential as a Chemoprotective Agent
-
September 10, 2021
Aileron Therapeutics to Present New Clinical Data at ESMO Virtual Congress 2021 Supporting Novel, Selective Chemoprotective Agent ALRN-6924
-
September 7, 2021
Aileron Therapeutics to Present at Upcoming H.C. Wainwright Virtual Global Investment Conference